Previous 10 | Next 10 |
CELG stock is currently on a good run of good news in 2019 after a few years of bad news from Celgene Corporation (NASDAQ:CELG). In May, the company secured US Food and Drug Administration approval for a combination of Rituxan and Revlimid, which is a second-line follicular lymphoma and...
This article is a continuation of a monthly series highlighting the top net payout yield (NPY) stocks that was started back in June 2012 and explained in August 2012 . The series highlights the best stocks for the upcoming month, utilized in part to make investment decisions for the IB Ass...
Bristol-Myers Squibb ( BMY ) is under considerable pressure, the stock has declined by more than 25% from its highs of the year due to generalized negativity towards the drug manufacturing sector and the uncertainty produced by the Celgene ( CELG ) acquisition. On the other hand, the busin...
Health Catalyst (NASDAQ: HCAT ) initiated with Buy rating and $49 (16% upside) price target at Goldman Sachs. Initiated with Buy rating and $53 price target at SunTrust, Outperform with a $50 a target at Evercore ISI, Outperform with a $55 target at SVB Leerink, Outperform at William Blair a...
Four of my favorite times of the trading year are the days that Form 13F filings are released. Those filings give all investors and traders a chance to see what the big money is buying, selling or holding. In particular I am interested in the funds that invest largely in M&A stocks. I tr...
INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC ® (fedratinib) for the treatment of adult patients with intermediate-2...
Under Priority Review status, FDA approves Celgene's ( CELG +0.6% ) Inrebic (fedratinib) for the treatment of a bone marrow disorder called intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocytopenia) myelofibrosis. More news on: Celgene ...
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 08/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a...
This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb's 13F stock portfolio on a quarterly basis. It is based on Third Point's regulatory 13F Form filed on 08/13/2019. Please visit our Tracking Dan Loeb's Third Point Portfolio series to get an i...
Daniel Loeb's Third Point hedge fund says it cut its stake in United Technologies ( UTX +1% ), becoming the second activist hedge fund to sell shares following the merger announcement with Raytheon. More news on: United Technologies Corporation, Tradeweb Markets Inc., American Express ...
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...